Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial

Post time 7 day(s) ago

journal：Circulation

Authors：Victorien Monguillon; Nicholas A. Marston; Erin A. Bohula; Jeong-Gun Park; Julia F. Kuder; Sabina A. Murphy; Gaetano M. De Ferrari; Lawrence A. Leiter; Jose C. Nicolau; Christoph Ebenbichler; Peter Sinnaeve; Assen Goudev; Andrzej Budaj; Oleg Averkov; Lale Tokgzolu; Ron Blankstein; Dragos Vinereanu; Robert P. Giugliano; Marc S. Sabatine; Michelle L. O’Donoghue

Published date：2026-6-23

DOI：10.1161/circulationaha.126.080999

PDF link：https://www.ahajournals.org/doi/ ... ATIONAHA.126.080999

Article link：https://doi.org/10.1161/circulationaha.126.080999

Article Source：Ovid Technologies (Wolters Kluwer Health)。

Remark：

Post time 7 day(s) ago

: This post has been completed
Completed attachments will be deleted within 24 hours.

[AHA] Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial Copy

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[AHA] Lipoprotein(a) Levels, Risk of Cardiovascular Events, and Benefit of Evolocumab: Findings From the VESALIUS-CV Trial